Bio Zdrowie Sp. z o.o.
- Address
- Ul. Lodowa 79/u2, 15-698 Bialystok, Poland
Respiratory Diseases
At Bio Zdrowie Sp. z o.o. in Bialystok, clinical research in respiratory tract diseases focuses on asthma and respiratory tract infections. The trials are designed to assess whether new or alternative treatments can improve symptom control and help reduce infections in different patient groups.
- Testing treatment effectiveness in mild to moderate asthma
- Evaluating new options for uncontrolled moderate to severe eosinophilic asthma
- Studying prevention of respiratory tract infections in children
This work reflects a strong interest in better management of chronic breathing conditions and infection prevention, with an emphasis on practical benefits for patients.
Immune System Diseases
Research in immune system diseases at this pharmaceutical company includes studies in chronic spontaneous urticaria, a condition marked by recurring hives and itching. The main goal is to evaluate whether new therapies can provide stronger and more reliable symptom relief than placebo.
- Assessing symptom improvement in chronic spontaneous urticaria
- Measuring changes in disease activity and patient comfort
- Exploring novel approaches for immune-driven skin symptoms
The site’s work in this area is centered on improving everyday quality of life for people affected by persistent allergic and immune-related conditions.
Skin and Connective Tissue Diseases
Clinical trials linked to skin and connective tissue diseases at the Poland-based site overlap with chronic spontaneous urticaria, where researchers are examining ways to reduce flare-ups and ease discomfort. These studies aim to support better control of visible and often disruptive skin symptoms.
- Investigating therapies for recurring urticaria symptoms
- Looking at improvements in itch and hives burden
- Supporting development of more effective skin-related treatments
Overall, the research combines dermatology and immunology to address conditions that can significantly affect daily well-being.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Chiesi Farmaceutici S.p.A.1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Bio Zdrowie Sp. z o.o.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b Dose-Ranging Study of Oral KT-621 in Adults with Uncontrolled Moderate to Severe Eosinophilic Asthma | Kymera Therapeutics Inc. | Phase II | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Glycopyrronium Bromide | 2 | Unknown | 2026-04-13 | 2026-04-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.